This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

PharmaPoint: Osteoporosis - China Drug Forecast And Market Analysis To 2022

NEW YORK, April 10, 2013 /PRNewswire/ -- announces that a new market research report is available in its catalogue:

PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022

PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022


GlobalData has released its new Country report, "PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022". Despite its maturity, the osteoporosis market is expected to undergo substantial change between 2012 and 2022. Most importantly, the 'gold-standard' bisphosphonates will lose patent protection by end-of-year 2013, flooding the marketplace with less expensive generic versions of these physician-preferred medications. Additionally, Eli Lilly's blockbuster Evista, the only available SERM in the US, will lose patent protection in 2014, flooding the market with yet more affordable generic options. Also during the forecast period covered by this report, osteoporosis drug development research will lead to the launches of a wave of novel anabolic drugs with greater efficacy and safety, causing a major market shift away from anti-resorptive drugs. The number of companies vying for patient share will shrink by as much as 50%, as established players exit the market or acquire smaller players. Lastly, the aging of the population in developed markets will result in a larger patient pool.

These changes in the osteoporosis market will be reflected in the slow growth during the forecast period, with the market growing from $6 billion to $8 billion in 2011 USD at a CAGR of 3%.

As in India, recession of the market for branded products will be caused by floods of generic products into the market. Like India, China will likely start issuing compulsory licenses for Chinese generics companies to violate IP rights and produce drugs prior to patent expiries. Therefore, GlobalData expects the Chinese market to be dominated by generic products, and to lose significant value in the branded side of the drug market. GlobalData did not project the pipeline products launching in the major markets because sales will likely be retarded by generic products.


- Overview of the Osteoporosis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.- Sales forecast for the top drugs in China from 2012-2022.- Analysis of the impact of key events as well the drivers and restraints affecting China Osteoporosis market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return- Stay ahead of the competition by understanding the changing competitive landscape for Osteoporosis- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential- Make more informed business decisions from insightful and in-depth analysis of drug performance- Obtain sales forecast for drugs from 2012-2022 in China

Table of Contents

1 Table of Contents 41.1 List of Tables 71.2 List of Figures 82 Introduction 92.1 Catalyst 92.2 Related Reports 93 Disease Overview 123.1 Etiology and Pathophysiology 123.1.1 Etiology 123.1.2 Pathophysiology 153.1.3 Risk Factors 163.1.4 Quality of Life 163.2 Symptoms 174 Disease Management 184.1 Treatment Overview 184.1.1 Diagnosis and Referral 184.1.2 Treatment Guidelines 194.1.3 Disease Management 204.2 China 234.2.1 Diagnosis 234.2.2 Clinical Practice 245 Competitive Assessment 255.1 Overview 255.2 Strategic Competitor Assessment 255.3 Product Profiles – Major Brands 295.3.1 Actonel (risedronate sodium) 295.3.2 Evista (raloxifene hydrochloride) 325.3.3 Reclast (zolendronic acid) 355.3.4 Forteo (teriparatide) 385.3.5 Prolia (denosumab) 425.3.6 Protelos (strontium ranelate) 455.3.7 Miacalcin and Fortical (calcitonin-salmon) 485.3.8 Viviant/Conbriza (bazedoxifene) 515.3.9 Recalbon/Bonoteo (minodronic acid hydrate) 54 5.3.10 Alendronate sodium 56 5.3.11 Ibandronate 586 Opportunity and Unmet Need 596.1 Overview 596.2 Unmet Needs 596.2.1 Disease Awareness and Early Diagnosis 596.2.2 Patient Compliance 606.2.3 Efficacy 616.2.4 Safety 616.2.5 Treatment Cost 626.2.6 Earlier Intervention 626.3 Unmet Needs Gap Analysis 636.4 Opportunity 1: Dual-Action Therapies 646.5 Opportunity 2: Osteoporosis Prevention Therapies 656.6 Opportunity 3: Dosing and Administration 657 Market Outlook 667.1 China 667.1.1 Forecast 667.1.2 Key Events 687.1.3 Drivers and Barriers 698 Appendix 708.1 Bibliography 708.2 Abbreviations 768.3 Methodology 798.4 Forecasting Methodology 798.4.1 Diagnosed Osteoporosis Patients 798.4.2 Percent Drug-Treated Patients 798.4.3 Drugs Included in Each Therapeutic Class 808.4.4 General Pricing Assumptions 808.4.5 Individual Drug Assumptions 808.4.6 Generic Erosion 848.5 Physicians and Specialists Included in this Study 858.5.1 About the Authors 868.5.2 Global Head of Healthcare 878.6 About GlobalData 888.7 Contact Us 888.8 Disclaimer 88

List of Tables

Table 1: Etiology of Primary Osteoporosis 12Table 2: Etiology of Secondary Osteoporosis 14Table 3: Symptoms of Osteoporosis 17Table 4: Diagnostic Tests for Osteoporosis 18Table 5: T-Score Ranges for Determination of BMD 19Table 6: Treatment Guidelines for Osteoporosis 20Table 7: Most Prescribed Drugs for Osteoporosis by Therapeutic Class in the Global Markets, 2012 21Table 8: Leading Treatments for Osteoporosis, 2012 28Table 9: Product Profile – Actonel 30Table 10: Actonel SWOT Analysis, 2012 31Table 11: Product Profile – Evista 33Table 12: Evista SWOT Analysis, 2012 34Table 13: Product Profile – Reclast 36Table 14: Reclast SWOT Analysis, 2012 37Table 15: Product Profile – Forteo 39Table 16: Mean Percent Change from Baseline in BMD with Forteo vs. Placebo in Postmenopausal Women with Osteoporosis 40Table 17: Forteo SWOT Analysis, 2012 41Table 18: Product Profile – Prolia 42Table 19: Prolia SWOT Analysis, 2012 44Table 20: Product Profile – Protelos 45Table 21: Protelos SWOT Analysis, 2012 46Table 22: Product Profile – Miacalcin and Fortical Nasal Spray 49Table 23: Adverse Events with Miacalcin Nasal Spray 49Table 24: Miacalcin and Fortical Nasal Spray SWOT Analysis, 2012 50Table 25: Product Profile – Viviant/Conbriza 52Table 26: Viviant/Conbriza SWOT Analysis, 2012 53Table 27: Product Profile – Recalbon/Bonoteo 54Table 28: Recalbon/Bonoteo SWOT Analysis, 2012 55Table 29: Overall Unmet Needs – Current Level of Attainment 59Table 30: Clinical Unmet Needs – Gap Analysis, 2012 63Table 31: China Sales Forecasts ($m) for Osteoporosis, 2012-2022 67Table 32: Key Events Impacting Sales for Osteoporosis in the China, 2012–2022 68Table 33: Osteoporosis Market – Drivers and Barriers in China, 2012–2022 69Table 34: Number of High-Prescribing Physicians Surveyed 85

List of Figures

Figure 1: Sales for Osteoporosis Drugs in China by Drug Class, 2012–2022 68

To order this report: Drug_and_Medication Industry: PharmaPoint: Osteoporosis - China Drug Forecast and Market Analysis to 2022

Contact Clare: US:(339) 368 6001 Intl:+1 339 368 6001

SOURCE Reportlinker

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.24 -0.41%
FB $117.81 -0.21%
GOOG $701.43 0.82%
TSLA $211.53 -4.96%
YHOO $36.94 2.61%


Chart of I:DJI
DOW 17,660.71 +9.45 0.05%
S&P 500 2,050.63 -0.49 -0.02%
NASDAQ 4,717.0940 -8.5450 -0.18%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs